Seeking Alpha
 

Optimer Pharmaceuticals, Inc. (OPTR)

- NASDAQ
OPTR is defunct.
  • Jul. 31, 2013, 9:12 AM
    | Comment!
  • Jul. 31, 2013, 8:43 AM
    | 1 Comment
  • Jul. 31, 2013, 8:07 AM
    • Credit Suisse upgrades Cubist Pharmaceuticals (CBST) to Outperform from Neutral following yesterday's announcement that the company is buying both Optimer Pharmaceuticals (OPTR) and Trius Therapeutics (TSRX).
    • CBST investors got a look at Dificid sales for Q2 courtesy of early numbers from OPTR Tuesday evening. Q2 sales of the antibacterial drug were $19M, up 13% from a disappointing $16.8M in Q1.
    • Ultimately, CBST sees Dificid and Trius' tedizolid bringing in a combined $600M to $1B per year, the company said on a CC convened to discuss the deals. (previous)
    • Premarket: CBST +6%, TSRX +17.3%, OPTR -6.55%.
    | Comment!
  • Jul. 30, 2013, 6:00 PM
    • Optimer (OPTR): Q2 EPS of -$0.55 beats by $0.07.
    • Revenue of $20.1M misses by $1.21M. Shares -8.2% AH.
    | Comment!
  • Jul. 30, 2013, 5:49 PM
    | Comment!
  • May 15, 2013, 4:01 PM
    Shares of Optimer Pharmaceutical (OPTR +15%) spike into the close on rumors that Cubist Pharmaceutical (CBST -0.5%) lobbed a $1B bid for OPTR prior to the sales process.
    | Comment!
  • May 13, 2013, 5:09 PM
    Shares of Optimer Pharmaceutical (OPTR +14%) ramped up into the close on reports that AstraZeneca (AZN), Astellas Pharma (ALPMY.PK) and Cubist Pharmaceuticals (CBST) are among the first round bidders for the antibiotic manufacturer. OPTR disclosed almost three months ago that they were working with Centerview Partners and JPMorgan to explore its strategic options, including a potential sale.
    | Comment!
  • May 10, 2013, 1:32 PM
    The sell-off in Optimer Pharmaceuticals (OPTR -16.6%) accelerates as the session drags on, with losses now well into the double-digits. On top of Needham's downgrade (disappointing Dificid sales may equate to less value for anyone planning an acquisition), Baird chimes in as well, cutting the shares to Neutral from Outperform (price target still $16). (earnings, CC)
    | Comment!
  • May 10, 2013, 12:52 PM
    Midday top 10 gainers: UNIS +58%. DRAM +57%. VRML +26%. SREV +22%. MCP +20%. UBNT +18%. RH +18%. WCRX +17%. CSIQ +16%. SQNM +16%.
    Midday top 10 losers: PTIE -48%. DRRX -41%. IFMI -34%. AFFY -26%. SRT -23%. LPDX -22%. OPTR -17%. REFR -16%. PANL -16%. TRMD -15%.
    | Comment!
  • May 10, 2013, 9:39 AM
    More on Optimer's (OPTR -8.2%) Q1 results: Dificid net sales of $16.8M versus $14.4M in Q1 2012. The company sees a 5% increase in demand for the product but Needham's Alan Carr notes that consensus estimates were for Dificid sales of $20M and worries that the "concerning" sales trajectory (0% growth Q/Q) could reduce the premium any potential suitor might be willing to pay to acquire the company. (PR)
    | Comment!
  • May 10, 2013, 9:10 AM
    Premarket gainers: PGNX +26%. UNIS +21%. UBNT +19%. SQNM +11%. MCP +11%. XIN +7%. NBG +6%. NTE +5%. MT +5%.
    Losers: PTIE -48%. IFMI -36%. AFFY -18%. SNTS -7%. OPTR -7%. DDD -6%. MDRX -6%. LFVN -5%.
    | Comment!
  • Apr. 2, 2013, 10:02 AM
    Optimer Pharmaceuticals (OPTR) surges 18.1% following a report that the antibiotics maker has attracted takeover interest from GlaxoSmithKline (GSK), AstraZeneca (AZN), Cubist Pharmaceuticals (CBST) and Japan's Astellas. Optimer hopes to fetch up to $1B in an auction, well above its market cap of $660M. The company has one drug on the market, Dificid, which is used to treat intestinal infections in hospitalized patients.
    | 1 Comment
  • Feb. 27, 2013, 12:55 PM
    Midday top 10 gainers: ZGNX +39%. UNXL +24%. FSGI +21%. GWRE +18%. ELMD +16%. PDCE +14%. OPTR +13%. DLTR +12%. END +11%. SHI +11%.
    Midday top 10 losers: AH -26%. CBB -23%. AMBO -22%. RNIN -21%. CBMX -19%. XWES -19%. FSLR -16%. CMGE -15%. CRMB -13%. PRPH -12%.
    | Comment!
  • Feb. 27, 2013, 10:31 AM
    Optimer Pharmaceuticals (OPTR +15%) says its board of directors has begun exploring a full range of strategic alternatives and has engaged JPMorgan and Centerview Partners as financial advisers. The board stated however, that there are no assurances that the review will result in any action and that there would be no further comment on the process until it's completed. The company also preannounced Q4 results of $0.02 per share, and appointed its chairman, Dr. Henry McKinnell, as CEO.
    | Comment!
  • Jan. 4, 2013, 5:50 PM
    After-hours top gainers, as of 5:15 p.m.: OPTR +16%. GTI +9%. DSLV +3%. EGLE +2%. GNMK +2%.
    After-hours top losers: MSPD -8%. CFFN -5%. G -4%. PL -4%. WCRX -2%.
    | Comment!
  • Jul. 31, 2012, 5:43 PM
    Optimer Pharma (OPTR): Q2 EPS of -$0.01 beats by $0.06. Revenue of $49.8M (+150809.1% Y/Y) beats by $0.33M. Shares -4.8% AH. (PR)
    | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for OPTR.
Sector: Healthcare
Industry: Biotechnology
Country: United States